Theratechnologies Inc. (THTX)
Market Cap | 80.20M |
Revenue (ttm) | 59.06M |
Net Income (ttm) | -21.58M |
Shares Out | 49.20M |
EPS (ttm) | -0.91 |
PE Ratio | n/a |
Forward PE | 55.87 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 25,491 |
Open | 1.56 |
Previous Close | 1.59 |
Day's Range | 1.55 - 1.67 |
52-Week Range | 0.88 - 5.96 |
Beta | 1.30 |
Analysts | Buy |
Price Target | 18.67 (+1,045.4%) |
Earnings Date | Sep 26, 2023 |
About THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulatio... [Read more]
Full Company ProfileFinancial Performance
In 2022, THTX's revenue was 80.06 million, an increase of 14.66% compared to the previous year's 69.82 million. Losses were -47.24 million, 48.9% more than in 2021.
Financial numbers in CAD Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for THTX stock is "Buy." The 12-month stock price forecast is $18.67, which is an increase of 1,045.40% from the latest price.
News

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer Honor aw...

Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercial...

Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

Theratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
MONTREAL, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million

Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
MONTREAL, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 202...

Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
MONTREAL, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
- Removal of Minimum Liquidity Covenant of US$30 Million if F8 Formulation of Tesamorelin is Not Approved by the FDA by March 31, 2024

Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
- 2023 Q3 positive adjusted EBITDA to be achieved - Cash, bonds and money market funds of US$22.9 million as at August 31, 2023 This news release constitutes a “designated news release” for the purpos...

Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
MONTREAL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite
TORONTO , Aug. 21, 2023 /PRNewswire/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his Company's story in ...

Theratechnologies Completes 1-for-4 Reverse Stock Split
MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and co...

Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023 This news release constitutes a “designated news release” for the purposes of the Com...

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
MONTREAL, July 21, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

Theratechnologies Announces 1-for-4 Reverse Stock Split
- Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listin...

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...